Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

被引：132

作者：

Lyke, Kirsten E. ^{[1
]}

Atmar, Robert L. ^{[2
]}

Islas, Clara Dominguez ^{[3
]}

Posavad, Christine M. ^{[3
,4
]}

Szydlo, Daniel ^{[5
]}

Chourdhury, Rahul Paul ^{[5
]}

Deming, Meagan E. ^{[1
]}

Eaton, Amanda ^{[6
]}

Jackson, Lisa A. ^{[7
]}

Branche, Angela R. ^{[8
]}

Sahly, Hana M. El ^{[2
]}

Rostad, Christina A. ^{[9
]}

Martin, Judith M. ^{[10
]}

Johnston, Christine ^{[3
,4
,11
]}

Rupp, Richard E. ^{[12
]}

Mulligan, Mark J. ^{[13
]}

Brady, Rebecca C. ^{[14
]}

Frenck, Robert W., Jr. ^{[14
]}

Backer, Martin ^{[15
]}

Kottkamp, Angelica C. ^{[13
]}

Babu, Tara M. ^{[11
]}

Rajakumar, Kumaravel ^{[10
]}

Edupuganti, Srilatha ^{[16
,17
]}

Dobrzynski, David ^{[8
]}

Coler, Rhea N. ^{[18
,19
]}

Archer, Janet I. ^{[20
]}

Crandon, Sonja ^{[21
]}

Zemanek, Jillian A. ^{[5
]}

Brown, Elizabeth R. ^{[3
]}

Neuzil, Kathleen M. ^{[1
]}

Stephens, David S. ^{[16
]}

Post, Diane J. ^{[21
]}

Nayak, Seema U. ^{[21
]}

Suthar, Mehul S. ^{[22
]}

Roberts, Paul C. ^{[21
]}

Beigel, John H. ^{[21
]}

Montefiori, David C. ^{[23
]}

机构：

[1] Univ Maryland Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA

[2] Baylor Coll Med, Dept Med & Mol Virol & Microbiol, Houston, TX 77030 USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA USA

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Stat Ctr HIV AIDS Res & Prevent SCHARP, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Duke Univ Med Ctr, Dept Surg, Durham, NC USA

[7] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA

[8] Univ Rochester, Dept Med, Div Infect Dis, Rochester, NY USA

[9] Emory Univ Sch Med & Childrens Healthcare Atlanta, Ctr Childhood Infect & Vaccines, Dept Pediat, Atlanta, GA USA

[10] Univ Pittsburgh Sch Med, Dept Pediat, Pittsburgh, PA USA

[11] Univ Washington, Dept Med, Seattle, WA USA

[12] Univ Texas Med Branch, Sealy Inst Vaccine Sci, Galveston, TX USA

[13] NYU Langone Vaccine Ctr, NYU Grossman Sch Med, Dept Med, Div Infect Dis & Immunol, New York, NY USA

[14] Univ Cincinnati Coll Med, Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH USA

[15] NYU Langone Hosp, Mineola, NY USA

[16] Emory Univ Sch Med, Dept Med, Atlanta, GA USA

[17] Hope Clin Emory Vaccine Ctr, Atlanta, GA USA

[18] Univ Washington Sch Med, Seattle Childrens Res Inst, Seattle, WA USA

[19] Univ Washington Sch Med, Dept Pediat, Seattle, WA USA

[20] FHI360, Durham, NC 27701 USA

[21] Natl Inst Allergy & Infect Dis, NIH, Div Microbiol & Infect Dis, Bethesda, MD USA

[22] Emory Univ, Atlanta, GA USA

[23] Duke Univ Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA

来源：

CELL REPORTS MEDICINE | 2022年 / 3卷 / 07期

基金：

美国国家卫生研究院;

关键词：

BA.2.12.1; BA.4/BA.5; booster; COVID-19; mRNA vaccine; neutralizing antibody; Omicron variant; recombinant adenovirus vaccine; SARS-CoV-2; sublineage;

D O I：

10.1016/j.xcrm.2022.100679

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to generate protective immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2.

引用

页数：13

共 18 条

[1]

Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]

[2] Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant [J].

Arien, Kevin K. ;

Heyndrickx, Leo ;

Michiels, Johan ;

Vereecken, Katleen ;

Van Lent, Kurt ;

Coppens, Sandra ;

Willems, Betty ;

Pannus, Pieter ;

Martens, Geert A. ;

Van Esbroeck, Marjan ;

Goossens, Maria E. ;

Marchant, Arnaud ;

Bartholomeeusen, Koen ;

Desombere, Isabelle .

NPJ VACCINES, 2022, 7 (01)

[3] Homologous and Heterologous Covid-19 Booster Vaccinations [J].

Atmar, R. L. ;

Lyke, K. E. ;

Deming, M. E. ;

Jackson, L. A. ;

Branche, A. R. ;

El Sahly, H. M. ;

Rostad, C. A. ;

Martin, J. M. ;

Johnston, C. ;

Rupp, R. E. ;

Mulligan, M. J. ;

Brady, R. C. ;

Frenck, R. W., Jr. ;

Backer, M. ;

Kottkamp, A. C. ;

Babu, T. M. ;

Rajakumar, K. ;

Edupuganti, S. ;

Dobrzynski, D. ;

Coler, R. N. ;

Posavad, C. M. ;

Archer, J., I ;

Crandon, S. ;

Nayak, S. U. ;

Szydlo, D. ;

Zemanek, J. A. ;

Islas, C. P. Dominguez ;

Brown, E. R. ;

Suthar, M. S. ;

McElrath, M. J. ;

McDermott, A. B. ;

Montefiori, D. C. ;

Eaton, A. ;

Neuzil, K. M. ;

Stephens, D. S. ;

Roberts, P. C. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11) :1046-1057

[4]

CDC, 2022, POT RAP INCR OM VAR

[5]

CDC, 2022, SCI BRIEF OM B 1 1 5

[6] Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines [J].

Collier, Ai-ris Y. ;

Yu, Jingyou ;

McMahan, Katherine ;

Liu, Jinyan ;

Chandrashekar, Abishek ;

Maron, Jenny S. ;

Atyeo, Caroline ;

Martinez, David R. ;

Ansel, Jessica L. ;

Aguayo, Ricardo ;

Rowe, Marjorie ;

Jacob-Dolan, Catherine ;

Sellers, Daniel ;

Barrett, Julia ;

Ahmad, Kunza ;

Anioke, Tochi ;

VanWyk, Haley ;

Gardner, Sarah ;

Powers, Olivia ;

Bondzie, Esther A. ;

Wan, Huahua ;

Baric, Ralph S. ;

Alter, Galit ;

Hacker, Michele R. ;

Barouch, Dan H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21) :2010-2012

[7] Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant [J].

Edara, Venkata Viswanadh ;

Norwood, Carson ;

Floyd, Katharine ;

Lai, Lilin ;

Davis-Gardner, Meredith E. ;

Hudson, William H. ;

Mantus, Grace ;

Nyhoff, Lindsay E. ;

Adelman, Max W. ;

Fineman, Rebecca ;

Patel, Shivan ;

Byram, Rebecca ;

Gomes, Dumingu Nipuni ;

Michael, Garett ;

Abdullahi, Hayatu ;

Beydoun, Nour ;

Panganiban, Bernadine ;

McNair, Nina ;

Hellmeister, Kieffer ;

Pitts, Jamila ;

Winters, Joy ;

Kleinhenz, Jennifer ;

Usher, Jacob ;

O'Keefe, James B. ;

Piantadosi, Anne ;

Waggoner, Jesse J. ;

Babiker, Ahmed ;

Stephens, David S. ;

Anderson, Evan J. ;

Edupuganti, Srilatha ;

Rouphael, Nadine ;

Ahmed, Rafi ;

Wrammert, Jens ;

Suthar, Mehul S. .

CELL HOST & MICROBE, 2021, 29 (04) :516-+

[8] Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination [J].

Edara, Venkata Viswanadh ;

Hudson, William H. ;

Xie, Xuping ;

Ahmed, Rafi ;

Suthar, Mehul S. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (18) :1896-1898

[9]

Edara Venkata-Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.12.20.473557

[10]

Edara Venkata-Viswanadh, 2021, bioRxiv, DOI 10.1101/2021.05.09.443299

← 1 2 →